Compare Microsoft (MSFT) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Nuwellis Inc — how do they compare? Microsoft trades at $527.86 (market cap $3.93T), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Microsoft is far larger — about 1786363.6× Nuwellis Inc's market cap, and Microsoft pays a 0.74% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Nuwellis Inc for 26 Days on average.
| MSFT | NUWE | |
|---|---|---|
Market Cap | $3.93T | $2.20M |
Volume | 16,040,951 | 121,544 |
Sector | Technology | Health |
52-Week High | $542.07 | $146.65 |
52-Week Low | $352.83 | $0.68 |
Typical Hold Time | 142 Days | 26 Days |
Enterprise Value | $3.91T | -$1.52M |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $529.76, up 0.09% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 forecast. Revenue and net income have shown robust growth, reaching $281.72B and $101.83B in 2025, respectively. Analyst consensus is overwhelmingly positive, with 82% buy ratings and a $571.76 price target, indicating potential upside from current levels.
The outlook for MSFT remains favorable due to its leadership in AI and cloud computing, though risks include heightened capital expenditure concerns and competitive pressures. The stock's valuation multiples, such as a P/E of 29.51, reflect premium pricing but are supported by high profitability margins and growth prospects. Investors should weigh the strong institutional support against macroeconomic and sector-specific volatility.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
